Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
Phase 2
Completed
- Conditions
- Early Breast Cancer
- Interventions
- Drug: monosialic gangliosidesOther: Placebo
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT04222790
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04223583
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital, Zhengzhou, Henan, China
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Phase 2
Completed
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Phase 1
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT04213898
Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients
Phase 2
Withdrawn
- Conditions
- Stage IV Breast Cancer
- Interventions
- Combination Product: surgery combined with systemic therapyOther: systemic therapy
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Henan Cancer Hospital
- Registration Number
- NCT04199520
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
Phase 1
- Conditions
- NSCLC
- Interventions
- Drug: Autologous dendritic cells pulsed with antigen
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04199559
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Phase 3
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: neoadjuvant chemoradiation therapyDrug: Paclitaxel, Cisplatin
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 456
- Registration Number
- NCT04138212
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment
Phase 1
- Conditions
- Cancer
- Interventions
- Biological: tumor neoantigen
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04087252
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Phase 2
Recruiting
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Phase 2
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT04063683
- Locations
- 🇨🇳
First Affiliated Hospital of Henan University of Science and Technolog, Luoyan, Henan, China
🇨🇳Henan cancer hospital, Zhengzhou, Henan, China
🇨🇳ANYANG Cancer Hospital, Anyang, Henan, China
© Copyright 2025. All Rights Reserved by MedPath